Skip to content

A comparative study on the safety and efficacy of etomidate or propofol in elderly patients: a multicenter, randomized and controlled study

A comparative study on the safety and effectiveness of etomidate or propofol in elderly patients

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000031524
Enrollment
Unknown
Registered
2020-04-03
Start date
2019-01-01
Completion date
Unknown
Last updated
2020-04-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cognitive dysfunction

Interventions

propofol group:propofol

Sponsors

Air Force Medical University of PLA (the Fourth Military Medical University)
Lead Sponsor

Eligibility

Sex/Gender
All
Age
65 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1) Aged 65-80 years; 2) Patients with laparoscopic / open gastrointestinal and hepatobiliary operations under general anesthesia and the operation time <= 4H; 3) ASA grades I to III; 4) BMI is 18.5-29.9 kg / m2 [BMI = weight (kg) / height (M2)] (2013 US "guidelines for the management of adult overweight and obesity); 5) In line with the ethics, the patient voluntarily tested and signed the informed consent.

Exclusion criteria

Exclusion criteria: 1) Any cerebrovascular accident occurred within 3 months, such as stroke, TIA, etc.; 2) Severe liver and kidney dysfunction (severe liver dysfunction: alt, conjugated bilirubin, AST, ALP, one of total bilirubin > 2 times of the upper limit of normal value; severe renal dysfunction: Cr clearance = 180/110 mm Hg (WHO-ISH hypertension guideline grade 3 hypertension); 6) Identify/suspect abuse or long-term use of narcotic sedatives and analgesics; 7) Take hormone or other immunosuppressant for more than 10 days within half a year or have a history of adrenal cortex inhibition or immune system disease; 8) Hypothyroidism; 9) With a history of asthma; 10) Reoperation within 3 months; 11) There are contraindications or allergies to test drugs and other narcotic drugs; 12) Patients who participated in other studies within 30 days.

Design outcomes

Primary

MeasureTime frame
BP;HR;cognitive function;SpO2;

Secondary

MeasureTime frame
Liver function;Kidney function;BIS;Cortisol, aldosterone and ACTH;VAS;

Countries

China

Contacts

Public ContactHongguang Bao

Nanjing First Hospital

tracy_kelvin@njmu.edu.cn+86 13952004380

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026